Pharmacological aspects of human and canine narcolepsy

Progress in Neurobiology

Volumn 52, Issue 1, 1997, Pages 27-78

  Nishino, Seiji ^a   Mignot, Emmanuel ^a  

^a Stanford California and Cofounder   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CODEINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; OPIATE DERIVATIVE;

CATAPLEXY; DOG; DRUG ACTIVITY; DRUG MECHANISM; HALLUCINATION; HUMAN; NARCOLEPSY; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; REM SLEEP; REVIEW; SOMNOLENCE;

EID: 0030955520     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(96)00070-6     Document Type: Article

References (453)

1. Åberg, A. (1981) Controlled cross-over study of a 5-HT uptake inhibiting and an NA uptake inhibiting antidepressant. Acta Psychiat. Scand. 63, 244-255.
2. Adie, W. (1926) Idiopathic narcolepsy: a disease sui generis; with remarks on the mechanism of sleep. Brain 49, 257-306.
3. Aguirre, M., Broughton, R. and Stuss, D. (1985) Does memory dysfunction exist in narcolepsy?. J. Clin. Expl Neurophysiol. 7, 14-24.
4. Akaoka, H., Roussel, B., Lin, J., Chouvet, G. and Jouvet, M. (1991) Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci. Lett. 123, 20-22.
5. Akimoto, H., Honda, Y. and Takahashi, Y. (1960) Pharmacotherapy in narcolepsy. Dis. Nerv. System 21, 704-706.
6. Akindele, M. O., Evans, J. I. and Oswald, I. (1970) Monoamine oxidase inhibitors, sleep and mood. Electroencephalogr. Clin Neurophysiol. 29, 47-56.
7. Aldrich, M. (1996) The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 46, 393-401.
8. Aldrich, M. S. (1989) Automobile accidents in patients with sleep disorders. Sleep 12, 487-494.
9. Aldrich, M. S. (1993) The neurobiology of narcolepsy-cataplexy. Progr. Neurobiol. 41, 533-541.
10. Aldrich, M. S. and Naylor, M. W. (1989) Narcolepsy associated with lesions of the diencephalon. Neurology 39, 1505-1508.
11. Aldrich, M. S. and Rogers, A. E. (1989) Exacerbation of human cataplexy by prazosin. Sleep 12, 254-256.
12. Alles, G. A. (1933) The comparative physiological actions of D-1-beta-phenylisopropylamines: presser effects and toxicity. J. Pharmacol. Expl Ther. 47,. Altshuler L.Szuba M. Course of psychiatric disorders in pregnancy: dilemmas in pharmacologic management Neurol. Clins12 1994 613-635
13. Alles, G. A. (1933) The comparative physiological actions of D-1-beta-phenylisopropylamines: presser effects and toxicity. J. Pharmacol. Expl Ther. 47,. Altshuler L.Szuba M. Course of psychiatric disorders in pregnancy: dilemmas in pharmacologic management Neurol. Clins12 1994 613-635
14. American Narcolepsy Association (1992) Stimulant medication survey. In: The Eye Opener, pp. 1-3. January 1992.
15. American Sleep Disorders Association (1991) ICSD -International Classification of Sleep Disorders: Diagnostic and Coding Manual. American Sleep Disorders Association: Rochester, Minnesota.
16. American Sleep Disorders Association (1992) The clinical use of the multiple sleep latency test. Sleep 15, 268-276.
17. American Sleep Disorders Association (1994) Practice parameters for the use of stimulants in the treatment of narcolepsy. Sleep 17, 348-351.
18. Anderson, M. W., Zendell, S. M., Morgan, J. P., Herrera, C. O., Rubinstein, M. L. and Spielman, A. J. (1987) The effects of methadone in narcolepsy. In: 5th International Congress of Sleep Research, p. 464. Copenhagen, Denmark, 28 June-3 July.
19. Aserinsky, E. and Kleitman, N. (1953) Regularly occuring periods of eye motility, and concomitant phenomena during sleep. Science 118, 273-274.
20. Aston-Jones, G. and Bloom, F. E. (1981) Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J. Neurosci. 1, 876-886.
21. Babcock, D. A., Narver, E. L., Dement, W. C. and Mitler, M. M. (1976) Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. Pharmacol. Biochem. Behav. 5, 599-602.
22. Baghdoyan, H. A., Lydic, R., Callaway, C. W. and Hobson, J. A. (1989) The carbachol-induced enhancement of desynchronized sleep signs is dose dependent and antagonized by centrally administered atropine. Neuropsychopharmacology 2, 67-79.
23. Baghdoyan, H. A., Monaco, A. P., Rodrigo-Angulo, M. L., Assens, F., McCarley, R. W. and Hobson, J. A. (1984) Microinjection of neostigmine into the pontine reticular formation of cats enhances desynchronized sleep signs. J. Pharmacol. Expl Ther. 231, 173-180.
24. Baker, T., Foutz, A., Neyman, V. and Dement, W. (1982) Canine model of narcolepsy: genetic and developmental determinants. Exp. Neurol. 75, 729-742.
25. Baker, T. L. and Dement, W. C. (1985) Canine narcolepsy-cataplexy syndrome: evidence for an inherited monoaminergic-cholinergic imbalance. In: Brain Mechanisms of Sleep, pp. 199-233. Eds D. J. McGinty, R. Drucker-Colin, A. Morrison and P. L. Parmeggiani. Raven Press: New York.
26. Baldessarini, R. J. (1983) How do antidepressants work? In: The Affective Disorders, pp. 243-260. Eds J. M. Davis and J. W. Mass. American Psychiatric Press: Washington, DC.
27. Baldy-Moulinier, M., Arguner, A. and Besset, A. (1976) Ultradian and circadian rhythms in sleep and wakefulness. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 485-498. Eds C. Guilleminault, W. C. Dement and P. Passouant. Spectrum Publications: New York.
28. Bastuji, H. and Jouvet, M. (1988) Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Progr. Neuropsychopharmacol. Biol. Psychiat. 12, 695-700.
29. Baumgarten, H. G. and Bushart, W. (1970) Treatment of narcolepsy with mono-amino-oxidase inhibitors and sympathomimetic agents. Eur. Neurol. 3, 97-104.
30. Bell, C., Dixie-Bell, D. and Thompson, B. (1986) Further studies on the prevalence of isolated sleep paraylsis in black subjects. J. Natl Med. Assoc. 78, 649-659.
31. Bell, I. R. (1976) Diet histories in narcolepsy. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 221-227. Eds C. Guilleminault, W. C. Dement and P. Passouant. Spectrum Publications: New York.
32. Besset, A., Tafti, M., Villemine, E. and Billiard, M. (1993) Effect du modafinil (300 mg) sur le sommeil, la somnolence et la vigilance du narcoleptique. Neurophysiol. Clin. 23, 47-60.
33. Billiard, M., Besset, A., Montplasier, J., Laffort, F., Goldberg, F., Weill, J. S. and Lubin, S. (1994) Modafinal: A double-blind multicentric study. Sleep 17, S107-S112.
34. Billiard, M., Besset, A. and Cadilhac, J. (1983) The clinical and polygraphic development of narcolepsy. In: Sleep/Wake Disorders: Natural History, Epidemiology and Longterm Evolution, pp. 171-185. Eds C. Guilleminault and E. Lugaresi. Raven Press: New York.
35. Billiard, M., Salva, M. Q., DeKoninck, J., Besset, A., Touchon, J. and Cadihac, J. (1986) Daytime sleep characterisitcs and their relationships with night sleep in the narcoleptic patient. Sleep 9, 167-174.
36. Birau, N., Meyer, C., Matubayashi, K. and Meier-Ewert, K. (1982) Melatonin serum concentration during the nocturnal sleep in narcoleptics. IRCS Med. Sci. 10, 814.
37. Black, D. W., Yates, W. R. and N. C., A. (1988) Schizophrenia, schizophreniform disorder, and delusional (paranoidal) disorders. In: Textbook of Psychiatry, pp. 357-402. Eds J. A. Talbott, R. E. Hales and S. C. Yudofsky. American Psychiatric Press: Washington.
38. Boehme, R., Baker, T., Mefford, I., Barchas, J., Dement, W. C. and Ciaranello, R. (1984) Narcolepsy: cholinergic receptor changes in an animal model. Life Sci. 34, 1825-1828.
39. Boivin, D. B., Lorrain, D. and Montplaisir, J. (1993a) Effects of bromocriptine on periodic limb movements in human narcolepsy. Neurology 43, 2134-2136.
40. Boivin, D. B. and Montplaisir, J. (1991) The effects of L-DOPA on excessive daytime sleepiness in narcolepsy. Neurology 41, 1267-1269.
41. Boivin, D. B., Montplaisir, J. and Lambert, C. (1993b) Effects of bromocriptine in human narcolepsy. Clin. Neuropharmacol. 16, 120-126.
42. Boivin, D. B., Montplaisir, J., Petit, D., Lambert, C. and Lubin, S. (1993c) Effect of modafinil on symptomatology of human narcolepsy. Clin. Neuropharmacol. 16, 46-53.
43. Boivin, D. B., Montplaisir, J. and Poirier, G. (1989) The effects of L-DOPA on periodic leg movements and sleep organization in narcolepsy. Clin. Neuropharmacol. 12, 339-345.
44. Bourgine, N., Claustrat, B., Besset, A. and Billiard, M. (1986) Melatonin plasma concentrations during day-time and night-time in narcoleptic subjects and controls. Sleep Res. 15, 46.
45. Bousquest, P., Feldman, J. and Schwartz, J. (1984) Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J. Pharmacol. Expl Ther. 230, 232-236.
46. Bowersox, S., Kilduff, T., Faul, K., Dement, W. C. and Ciaranerlo, R. D. (1987a) Brain dopamine receptor levels elevated in canine narcolepsy. Brain Res. 402, 44-48.
47. Bowersox, S. S., Kilduff, T. S., Dement, W. C. and Ciaranello, R. D. (1987b) Brainstem cholinergic receptor abnormalities in canine narcolepsy are not associated with abnormalities in acetylcholinesterace, choline acetyltransferase, or choline uptake. Sleep 16, 313.
48. Bricca, G., Dontenwill, M., Molines, A., Feldman, J., Belcourt, A. and Bousquet, P. (1988) Evidence for the existence of a homogenous population of imidazoline receptors in the human brainstem. Eur. J. Pharmacol. 150, 401-402.
49. Bricca, G., Dontenwill, M., Molines, A., Feldman, J., Belcourt, A. and Bousquet, P. (1989) The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. Eur. J. Pharmacol. 162, 1-9.
50. Broughton, R., Dunham, W., Newman, J., Lutley, K., Dushesne, P. and Rivers, M. (1988a) Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched control. Electroencephalogr. Clin. Neurophysiol. 70, 473-481.
51. Broughton, R., Duschene, P., Aguirre, M., Newman, J. and Lutley, K. (1988b) A single nap is as acurate as the MSLT in diagnosing EDS in narcolepsy-cataplexy. Sleep Res. 17, 150.
52. Broughton, R. and Ghanem, Q. (1976) The impact of compound narcolepsy on the life of the patient. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 201-220. Eds C. Guilleminault, D. W. C. and P. Passouant. Spectrum: New York.
53. Broughton, R., Ghanem, Q., Hishikawa, Y., Sugita, Y., Nevsimalova, S. and Roth, B. (1981) Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. J. Can. Sci. Neurol. 8, 299-303.
54. Broughton, R., Ghanem, Q., Hishikawa, Y., Sugita, Y., Nevsimalova, S. and Roth, B. (1983) Life effects of narcolepsy; Relationships to geographic origin (North American, Asian or European) and to other patient and illness variables. Can. J. Neurol. Sci. 10, 100-104.
55. Broughton, R., Guberman, A. and Roberts, J. (1984) Comparison of psychosocial effects of epilepsy and of narcolepsy-cataplexy: a controlled study. Epilepsia 25, 423-433.
56. Broughton, R. and Mamelak, M. (1976) Gamma-hydroxybutyrate in the treatment of compound narcolepsy: a preliminary report. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 59-67. Eds C. Guilleminault, D. W. C. and P. Passouant. Spectrum: New York.
57. Broughton, R. and Mamelak, M. (1979) The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. J. Can. Sci. Neural. 6, 1.
58. Broughton, R. and Mamelak, M. (1980) Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. J. Can. Sci. Neurol. 7, 23.
59. Broughton, R., Valley, V., Aguirre, M., Roberts, J., Suwalski, W. and Dunham, W. (1986) Excessive daytime sleepiness and pathophysiology of narcolepsy-cataplexy: a laboratory perspective. Sleep 9, 105-215.
60. Broughton, W. A. and Broughton, R. J. (1994) Psychosocial impact of narcolepsy. Sleep 17, S45-S49.
61. Browman, C. P., Gujavarty, K. S., Yolles, S. F. and Mitler, M. M. (1986) Forty-eight-hour polysomnographic evaluation of narcolepsy. Sleep 9, 183-188.
62. Bruck, D., Amstrong, S. and Coleman, G. (1994) Sleepiness after glucose in narcolepsy. J. Sleep Res. 3,.
63. Brunel P. Vial T. Roche I. Bertolotti E. Evreux J. C. Follow-up of 151 pregant women exposed to antidepressant treatment (MAOI excluded) during organogenesis Therapie49 1994 117-122
64. Buist, A., Norman, T. R. and Dennerstein, L. (1990) Breastfeeding and the use of psychotropic medication: a review. J. Affect. Disord. 19, 197-206.
65. Bédard, M., Jacques, M., Godbout, R. and Lapierre, O. (1989) Nocturnal γ-hydroxybutyrate. Clin. Neuropharmacol. 12, 29-36.
66. Carlander, B. (1994a) Les autres causes de somnolence pathologiques. In: Le Sommeil Normal et Pathologique, pp. 288-294. Ed. M. Billard. Masson: Paris.
67. Carlander, B. (1994b) Traitement de la narcolepsie et autres formes d'excès de sommiel. In: Le Sommeil Normal et Pathologique, pp. 295-302. Ed. M. Billiard. Masson: Paris.
68. Carskadon, M. A., Dement, W. C., Mitler, M. M., Roth, T., Westbrook, P. R. and Keenan, S. (1986) Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 9, 519-524.
69. Challamel, M. J., Mazzola, M. E., Nevsimalova, S., Cannard, C., Louis, J. and Revol, M. (1994) Narcolepsy in children. Sleep 17, S17-S20.
70. 3H]nisoxetine binding sites in the cat brain: an autoradiographic study. Neuroscience 69, 259-270.
71. Chase, M. H. and Morales, F. R. (1990) The atonia and myoclonia of active (REM) sleep. Annu. Rev. Psychol. 41, 557-584.
72. Chayasirisobhon, S., Cullis, P. and Veeramasunemi, R. (1983) Occurence of neuroleptic malignant syndrome in a narcoleptic patient. Hasp. Commun. Psychiat. 34, 548-550.
73. Chetrit, M., Besset, A., Damci, D., Lelarge, C. and Billiard, M. (1994) Hypnogogic hallucinations associated with sleep onset REM period in narcolepsy-cataplexy. J. Sleep Res. 3, 43.
74. Chin, M. Y., Kreutzer, R. A. and Dyer, J. E. (1992) Acute poisoning from gammahydroxybutyrate in California. West. J. Med. 156, 380-384.
75. Chiueh, C. C. and Moore, K. E. (1974) Relative potencies of D-and L-amphetamine on the release of dopamine from cat brain in vivo. Res. Comm. Chem. Pathol. Pharmacol. 7, 189-199.
76. Chokroverty, S. (1986) Sleep apnea in narcolepsy. Sleep 9, 250-253.
77. Ciliax, B. J., Heilman, C., Demchyshyn, L. L., Pristupa, Z. B., Ince, E., Hersch, S. M., Niznik, H. B. and Levey, A. I. (1995) The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci. 15, 1714-1723.
78. Clark, R. (1980) Treatment of narcolepsy. Arch. Neurol. 37, 736.
79. Clark, R. L., Robertson, R. T., Minsker, D. H., Cohen, S. M., Tocco, D. J., Allen, H. L., James, M. L. and Bokelman, D. L. (1984) Diflunisal-induced maternal anemia as a cause of teratogenicity in rabbits. Teratology 30, 319-332.
80. Cohen, F. L. and Smith, K. M. (1989) Learning and memory in narcoleptic patients and controls. Sleep Res. 18, 117.
81. Cohen, R. M., Pickar, D., Garnett, D., Lipper, S., Gillin, J. C. and Murphy, D. L. (1982a) REM sleep suppression induced by selective monoamine oxidase inhibitors. Psychopharmacology 78, 137-140.
82. Cohen, R. M., Picker, D., Garnett, D., Lipper, S., Gillin, J. C. and Murphy, D. L. (1982b) REM sleep suppression induced by selective monoamine oxidase inhibitors. Psycopharmacology 78, 137-140.
83. Connell, P. H. (1958) Amphetamine Psychosis. Oxford University Press: London.
84. Dahlitz, M. and Parkes, J. D. (1993) Sleep paraylsis. Lancet 341, 406-407.
85. Daniels, L. E. (1934) Narcolepsy. Medicine 13, 1-122.
86. Dawdall, M. and DeMontigny, C. (1984) Pre- and post-sysnaptic effects of trazodone on serotonin neurotransmission: single cell studies in the rat. Neurosci. Abstr. 10, 17.
87. Delashaw, J., Foutz, A., Guilleminault, C. and Dement, W. (1979a) Effects of pharmacological alterations of acetylcholine on cataplexy in dogs. Sleep 8, 180.
88. Delashaw, J. B., Foutz, A. S., Guilleminault, C. and Dement, W. C. (1979b) Cholinergic mechanisms and cataplexy in dogs. Expl Neurol. 66, 745-757.
89. Dement, W., Rechtschaffen, A. and Gulevich, G. (1966) The nature of the narcoleptic sleep attack. Neurology 16, 18-33.
90. Dement, W. C. (1976) Daytime sleepiness and sleep 'attacks'. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 17-42. Eds C. Guilleminault, W. C. Dement and P. Passouant. Spectrum Publications: New York.
91. Dement, W. C., Carskadon, M. and Ley, R. (1973) The prevalence of narcolepsy II. Sleep Res. 2, 147.
92. Dement, W. C., Zarcone, W. and Varner, V. (1972) The prevalance of narcolepsy. Sleep Res. 1, 148-149.
93. Depoortere, H. (1988) Effect of 5HT1a-agonists on the sleep-wakefulness cycle in rats. In: Sleep '86, pp. 346-348. Eds W. P. Koella, F. Obál, H. Schulz and P. Visser. Gastav Fisher-Verlag: Stuttgart.
94. Di Chiara, G., Porceddu, M. L., Vargiu, L., Argiolas, A. and Gessa, G. L. (1976) Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 264, 564-567.
95. Divac, I. (1975) Magnocellular nuclei of the basal forebrain project to neocortex, brain stem, and olfactory bulb. Review of some functional correlates. Brain Res. 93, 385-398.
96. Douglass, A., Hays, P., Pazderka, F. and Russel, J. M. (1991) Florid refractory schizophrenias that turn out to be treatable variants of HLA associated narcolepsy. J. Nerv. Ment. Dis. 179, 12-17.
97. Duteil, J., Rambert, F. A., Pessonnier, J., Hermant, J., Gombert, R. and Assous, E. (1990) Central a1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil: studies with experimental animals. Eur. J. Pharmacol. 180, 49-58.
98. Dzoljic, M. R., Ukponmwan, O. E. and Saxena, P. R. (1992) 5-HT1-like receptor agonists enhance wakefulness. Neuropharmacology 31, 623-633.
99. Edgar, D. M., Seidel, W. F., Contreras, P., Vaught, J. L. and Dement, W. C. (1994) Modafinil promotes EEG wake without intensifying motor activity in the rat. Can. J. Physiol. Pharmacol. 72, 362.
100. Elwes, R. D. C., Crewes, H., Chesterman, Summers, B., Jenner, P., Binnie, B. and Parkes, J. D. (1988) Treatment of narcolepsy with L-tyrosine: double-blind placebo-controlled trial. Lancet 2, 1067-1069.
101. Engel, W. K., Siddique, T. and Nicoloff, J. (1983) Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releaseing hormone. Lancet 2, 73-75.
102. Ersmark, B. and Sjukhuset, K. (1973) Trial with amantadine in narcolepsy. Psychopharmacology 28, 308.
103. Fail, L. (1973) Narcolepsy and neurosis. Med. J. Austr. 2, 223-225.
104. Fischer, F. (1878) Epileptoide schlafzustände. Arch. Psychiat. 8, 200-203.
105. Foutz, A., Mitler, M., Cavalli-Sforza, L. and Dement, W. C. (1979) Genetic factors in canine narcolepsy. Sleep Res. 1, 412-413.
106. Foutz, A. S., Delashaw, J. B., Guilleminault, C. and Dement, W. C. (1981) Monoaminergic mechanisms and experimental cataplexy. Ann. Neurol. 10, 369-376.
107. Frederickson, R. C., Slater, I. H. and Dusenberrry, W. E. (1977) A comparison of thalidomide and pentobarbital -new methods for identifying novel hypnotic drugs. J. Pharmacol. Expl Ther. 203, 240-251.
108. Freemon, F. R. (1985) The treatment of narcolepsy and cataplexy. Compr. Ther. 11, 44-47.
109. Fry, J. and the U.S. Modifinal Study Group (1996) A New Alternative in the Pharmacologic Management of Somnolence: A Phase III Study of Modafinil in Narcolepsy. American Neurological Association: Miami, FL.
110. Fry, J. M., Pressman, M. R., DiPhillipo, M. A. and Forst-Paulus, M. (1986) Treatment of narcolepsy with codeine. Sleep 9, 269-274.
111. Fujimori, M. and Himwich, H. E. (1969) Electroencephalographic analyses of amphetamine and its methoxy derivatives with reference to their sites of EEG alerting in the rabbit brain. Intl J. Neuropharmacol. 8, 601-613.
112. Fukuda, K., Miyasita, A., Inugami, M. and Ishihara, K. (1987) High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan. Sleep 10, 279-286.
113. Fuller, R. W., Snoddy, H. D., Perry, K. W., Bymaster, F. P. and Wong, D. T. (1977) Importance of duration of drug action in the antagonisim of p-chloroamphetamine depletion of brain serotonin - comparison of fluoxetine and chlorimipramine. Biochem. Pharmacol. 27, 193-198.
114. Garattini, S. and Mennini, T. (1988) Clinical notes on the specificity of drugs in the study of metabolim and functions of brain monoamines. Intl Rev. Neurobiol. 29, 259-280.
115. Garcia-Rill, E. (1991) The pedunculopontine nucleus. Progr. Neurobiol. 36, 363-389.
116. Gélineáu (1880) De la narcolepsie. Gaz. Hôp. 53, 626-628.
117. Gelb, M., Guilleminault, C., Kraemer, H., Lin, S., Moon, S., Dement, W. C. and Mignot, E. (1994) Stability of cataplexy over several months -information for the design of therapeutic trials. Sleep 17, 265-273.
118. Genton, P., Benlakhel, K., Disdier, P., Leprince, Y., Lavernhe, G., Viallet, F. and Millet, Y. (1995a) Diagnosis of narcolepsy-cataplexy: importance of continuous recording in ambulatory EEG. Report of 20 cases. Neurophysiol. Clin. 25, 187-195.
119. Genton, P., Benlakhel, K., Disdier, P., Leprince, Y., Lavernhe, G., Viallet, F. and Millet, Y. (1995b) Diagnostic de la narcolepsy-cataplexie: intérêt de l'enregistrement continu sous EEG ambulatoire. À propos de 20 observations. Neurophysiol. Clin. 25, 187-195.
120. George, R., Haslett, W. L. and Jenden, D. J. (1964) A cholinergic mechanism in the brainstem reticular formation: induction of paradoxical sleep. Intl J. Neuropharmacol. 3, 541-552.
121. Gernaat, H. B. P. E., Hoffmans, P. M. J., Knegtering, H. and Birkenhager, T. K. (1995) Tranylcypromine in narcolepsy. Pharmacopsychiatry 28, 98-100.
122. Gillin, J. C., Horwitz, D. and Wyatt, R. J. (1976) Pharmacologic studies of narcolepsy involving serotonin, acetylcholine, and monoamine oxidase. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 585-603. Eds C. Guilleminault, W. C. Dement and P. Passouant. Spectrum Publications: New York.
123. Godbout, R. and Montplaisir, J. (1985) Comparison of sleep parameters in narcoleptics with and without periodic movements of sleep. In: Sleep '84, pp. 380-382. Eds W. P. Koella, E. Ruther and H. Schulz. Fischer Verlag: Gustav.
124. Godbout, R., Poirier, G. and Montplaisir, J. (1988) New Treatment for narcolepsy (viloxazine). In: Narcolepsy 3rd International Symposium, pp. 79-81. Eds S. A. Burton, W. C. Dement and R. Ristanovic: San Diego, CA.
125. Golbe, L. I. (1988) Deprenyl as symptomatic therapy in Parkinson's disease. Clin. Neuropharmacol. 11, 387-400.
126. Goldberg, M. R. and Robertson, D. (1983) Yohimbine: a pharmacological probe for study of the α2 adrenoceptor. Pharmacol. Rev. 35, 143-180.
127. Goode, B. (1962) Sleep paralysis. Arch. Neurol. 6, 228-234.
128. Guilleminault, C. (1987) Narcolepsy and its differential diagnosis. In: Sleep and it Disorders in Children, pp. 181-194. Ed. C. Guilleminault. Raven Press: New York.
129. Guilleminault, C. (1993) Amphetamine and narcolepsy: use of the Stanford database. Sleep 16, 199-201.
130. Guilleminault, C., Billiard, M. J. M. and Dement, W. (1975) Altered states of conciousness in disorders of daytime sleepiness. J. Neurol. Sci. 26, 377-393.
131. Guilleminault, C., Castaigne, P. and Pierre-Henri, C. (1972) Observations on the effectiveness of amantadine, L-dopa, L-dopa plus dopa decarboxylase inhibitor and dopa decarboxylase inhibitor in the treatment of narcolepsy. In: The Association for the Psychophysiological Sudy of Sleep 11th Annual Meeting, pp. 159. New York.
132. Guilleminault, C. and Dement, W. C. (1977) 235 cases of excessive daytime sleepiness: diagnosis and tentative classification. J. Neural. Sci. 31, 13-27.
133. Guilleminault, C., Dement, W. C. and Passouant, P. (1976a) Narcolepsy (Advances in Sleep Research Vol. 3). Spectrum Publications: New York.
134. Guilleminault, C., Mancuso, J., Salva, M. A. Q., Hayes, B., Mitler, M., Poirier, G. and Montplaisir, J. (1986) Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep 9, 275-279.
135. Guilleminault, C., Mignot, E., Aldrich, M., Quera-Salva, M. A., Tiberge, M. and Partinen, M. (1988) Prazosin contraindicated in patients with narcolepsy. Lancet 609, 511-512.
136. Guilleminault, C., Mignot, E. and Partinen, M. (1994) Controversies in the diagnosis of narcolepsy. Sleep 17, S1-S6.
137. Guilleminault, C., Raynal, D., Takahashi, S., Carskdon, M. and Dement, W. (1976b) Evaluation of short-term and long-term treatment of the narcolepsy sydrome with clomipramine hydrochloride. Acta Neurol. Scand. 54, 71-87.
138. Guilleminault, C., Wilson, R. A. and Dement, W. C. (1974) A study on cataplexy. Arch. Neural. 31, 255-261.
139. Gunne, L. M. and Lidvall, H. F. (1966) The urinary output of catecholamines in narcolepsy under resting conditions and following administration of dopamine, DOPA and DOPS. Scand. J. Clin. Lab. Invest. 18, 425-430.
140. Gunne, L. M., Lidvall, H. F. and Widén, L. (1971) Preliminary clinical trial with L-dopa in narcolepsy. Psychopharmacologia 19, 204-206.
141. Gunzler, V. (1992) Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations. Drug Safety 7, 116-134.
142. Hajek, M., Meier-Ewert, K., Wirt-Justice, A., Tobler, I., Arendt, J., Dick, H. and Fink, G. (1989) Bright white light does not improve narcoleptic symptoms. Eur. Arch. Psychiat. Neurol. Sci. 238, 203-207.
143. Harada, S., Matuski, K., Honda, Y. and Someya, T. (1988) Disorders of excessive daytime sleepiness without cataplexy, and their relationship with HLA in Japan. In: HLA in Narcolepsy, pp. 172-185. Eds Y. Honda and T. Juji. Springer Verlag: New York.
144. Harper, J. M. (1981) Gelineau's Narcolepsy relieved by opiates. Lancet 10, 92.
145. Hartse, K., Roth, T. and Zorick, F. J. (1982) Daytime sleepiness and daytime wakefulness: the effect of instruction. Sleep 5, 107-118.
146. Henneberg, R. (1916) Uber genuine narkolepsie. Neurol. Zbl. 30, 282-290.
147. Henry, G. K., Hart, R. P., Kwentus, J. A. and Sicola, M. J. (1988) Effects of protriptyline on vigilance and information processing in narcolepsy. Psychopharmacology 95, 109-112.
148. Hermant, J. F., Rambert, F. A. and Deuteil, J. (1991) Lack of cardiovascular effects after administartion of modafinil in conscious monkeys. Fundament. Clin. Pharmacol. 5, 825.
149. Hernandez-Peon, R., Chavez-Ibarra, G., Morgane, P. J. and Timo-Iaria, C. (1963) Limbic cholinergic pathways involved in sleep and emotional behavior. Expl Neurol. 8, 93-111.
150. Hirschfeld, R. M. A. and Goodwin, F. K. (1988) Mood diorders. In: Textbook of Psychiatry, pp. 403-441. Eds J. A. Talbott, R. E. Hales and S. C. Yudofsky. American Psychiatric Press: Washington.
151. Hishikawa, Y. (1976) Sleep paralysis. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 97-124. Eds C. Guilleminault, W. C. Dement and P. Passpouant. Spectrum Publications: New York.
152. Hishikawa, Y., Ida, H., Nakai, K. and Kaneko, Z. (1965) Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran). J. Neurol. Sci. 3, 453-461.
153. Hishikawa, Y., Koida, H., Yoshino, K., Wakamatsu, H., Sugita, Y., Iijima, S. and Nan'no, H. (1978) Characteristics of REM sleep accompanied by sleep paralysis and hypnogogic hallucinations in narcoleptic patients. Waking and Sleeping 2, 113-123.
154. Hishikawa, Y., Nan'no, H. and Tachibana, M. (1968) The nature of sleep attack and other symptoms of narcolepsy. Electroencephalogr. Clin. Neurophysiol. 24, 1-10.
155. Hishikawa, Y. and Shimizu, T. (1995) Physiology of REM sleep, cataplexy, and sleep paralysis. In: Negative Motor Phenomena Vol. 67, pp. 245-271. Eds S. Fahn, M. Hallet and H. O. Lüdersand. Lippincot-Raven Publishers: Philadelphia, PA.
156. Hishikawa, Y., Wakamatsu, H., Furuya, E., Sugita, Y., Masaoka, S., Kaneda, H., Sato, M., Nan'no, H. and Kaneko, Z. (1976) Sleep satiation in narcoleptic patients. Electroencephalogr. Clin. Neurophysiol. 41, 1-18.
157. Hobson, J. A., Datta, S., Calvo, J. M. and Quattrochi, J. (1993) Acetylcholine as a brain state modulator: triggering and term regulation of REM sleep. In: Progress in Brain Research: Cholinergic Function and Dysfunction Vol. 98. Ed. A. C. Cuello. Elsevier: Amsterdam.
158. Hobson, J. A., Quattrochi, J., Binder, D., Williams, J. and Mamelak, A. (1990) Dynamic supression of REM sleep by parenteral administration of the serotonin lab agonist, eltoprazine. Sleep Res. 19, 17.
159. Hohagen, F., Mayer, G., Memche, A., Riemann, D., Volk, S., Meirer-Ewert, K. and Berger, M. (1993) Treatment of narcolepsy-cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine - a pilot study. J. Sleep Res. 2, 250-256.
160. Honda, Y. (1988) Clinical features of narcolepsy. In: HLA in Narcolepsy, pp. 24-57. Eds Y. Honda and T. Juji. Springer-Verlag: Berlin.
161. Honda, Y., Asake, A., Tanaka, Y. and Jujui, T. (1983) Discrimination of narcolepsy by using genetic markers and HLA. Sleep Res. 12, 254.
162. Honda, Y., Hishikawa, Y. and Takahashi, Y. (1979) Long term treatment of narcolepsy with Ritalin (methylphenidate). Curr. Ther. Res. 25, 288-298.
163. Hood, B. and Bruck, D. (1996) Sleepiness and performance in narcolepsy. J. Sleep Res. 5, 128-134.
164. Hublin, C., Partinen, M., Heinonen, E. H. and Salmi, R. (1994a) Selegiline in the treatment of narcolepsy. Neurology 44, 2095-2101.
165. Hublin, C., Partinen, M., Kaprio, J., Koskenvuo, M. and Guilleminault, C. (1994b) Epidemiology of narcolepsy. Sleep 17, S7-S12.
166. Hudson, J. I. and Pope, H. G. (1990) Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology?. Am. J. Psychiat. 147, 552-564.
167. Hull, K. M. and Maher, T. J. (1992) Effects of L-tyrosine on mixed-acting sympathomimetic-induced pressor actions. Pharmacol. Biochem. Behav. 43, 1047-1052.
168. Iijima, S. and Hishikawa, Y. (1987) Narcolepsy (in Japanese). Clin. Neurosci. 5, 51-53.
169. Iijima, S., Sugita, Y., Teshima, Y. and Hishikawa, Y. (1986) Therapeutic effects of mazindol on narcolepsy. Sleep 9, 265-268.
170. Jacob, C. O., Fronek, Z. and Lewis, G. D. (1990) Heritable major histocompatibility complex class associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc. natn. Acad. Sci. U.S.A. 87, 1233-1237.
171. Jasper, H. H. and Tessier, J. (1971) Acetylcholine liberation from cerebral cortex during paradoxical (REM) sleep. Science 171, 601-602.
172. Jimbo, M., Takahaski, Y. and Suzuki, J. (1963) Polygraphic studies of nocturnal sleep of narcoleptics II. The effects of some psychotropic drugs on the appearance of paradoxical phases and hypnagogic hallucinations. In: Proc. 12th Annu. Mtg Japan EEG Soc., pp. 182.
173. Jones, B. E. (1991) Paradoxical sleep and its chemical/structural substrates in the brain. Neuroscience 40, 637-656.
174. Jones, B. E. and Beaudet, A. (1987) Retrograde labeling of neurons in the brainstem following injection of [3H]-choline into the forebrain of the rat. Expl Brain Res. 65, 437-467.
175. Kaitin, K., Kilduff, T. and Dement, W. C. (1986a) Evidence for excessive sleepiness in canine narcoleptics. Electroencephalogr. Clin. Neurophysiol. 64, 447-454.
176. Kaitin, K. I. (1985) Effects of thalidomide and pentobarbital on neuronal activity in the preoptic area during sleep and wakefulness in the cat. Psychopharmacology 85, 47-50.
177. Kaitin, K. I., Kilduff, T. S. and Dement, W. C. (1985a) A comparison of 24-hour recordings in genetically narcoleptic and control dogs. Neurosci. Abstr. 11, 1284.
178. Kaitin, K. I., Kilduff, T. S. and Dement, W. C. (1986b) Sleep fragmentation in genetically narcoleptic dogs. Sleep 9, 116-119.
179. Kaitin, K. K., Kilduff, T. S. and Dement, W. C. (1985b) Sleep organization in the genetically narcoleptic dog. Sleep 14, 174.
180. Kajaste, S., Oramem, M., Partinen, M. and Hublin, C. (1989) Rehabilitation program for narcoleptic patients and its impact on quality of life. Arch. Found. Thanatol. 16.
181. Kales A. Cadieux R. Soldatos C. R. Tan T. L. Successful treatment of narcolepsy with propranolol Arch. Neurol.36 1979 650-651
182. Kales, A., Cadieux, R. J. and Soldatos, C. R. (1982) Narcolepsy-cataplexy I. Clinical and electrophysiologic characteristics. Arch. Neurol. 39, 164-168.
183. Kalra, M. and LL, H. (1992) Gammahydroxybutyrate in narcolepsy. Ann. Pharmacother. 26, 647-648.
184. Kanbayashi, T., Nishino, S., Tafti, M., Hishikawa, Y., Dement, W. C. and Mignot, E. (1996a) Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. NeuroReport 12, 1881-1886.
185. Kanbayashi, T., Nishino, S., Tafti, M., Hishikawa, Y., Dement, W. C. and Mignot, E. (1996b) Thalidomide, immune modulation and narcolepsy. Sleep 19, 116.
186. Kaneko, Y., Kumashiro, H., Maruko, K., Yashima, U. and Suzuki, N. (1977) Ergotamine tartrate in the treatment of narcolepsy. Br. J. Psychiat. 131, 549.
187. Kaneko, Y., Takahashi, Y., Kaneko, M. and Kumashiro, H. (1978) Therapeutic usefulness of ergotamine tartrate for narcolepsy. Am. J. Psychiat. 135, 873-874.
188. Kaplan, G. (1994) Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology 191, 564-568.
189. Karczmar, A. G., Longo, V. G. and De Carolis, S. (1970) A pharmacological model of paradoxical sleep: the role of cholinergic and monoaminergic systems. Physiol. Behav. 5, 175-182.
190. Kastin, A., Ehrensing, R., Schalach, D. and Anderson, M. (1972) Improvement in mental depression with decreased thyrotropin response after administration of thyrotropin-releasing hormone. Lancet, 740-742.
191. Kendel, K., Rüther, E., Beck, C. and Meier-Ewert, K. (1973) Zur behandlung der narkolepsie mit L-dopa. Nervenarzt 44, 434-436.
192. Kilduff, T., Bowersox, S. S., Kaitan, K. I., Baker, T. L., Ciaranello, R. D. and Dement, W. C. (1986) Muscarinic cholinergic receptors and the canine model of narcolepsy. Sleep 9, 102-107.
193. Kilduff, T. S., Radde, L., Burtch, M., Steinman, L. and Dement, W. C. (1987) Immunosuppression with cyclosporine as a treatment for canine narcolepsy. Sleep 16, 369.
194. Knecht, C. D., Oliver, J. E., Redding, R., Selcer, R. and Johnson, G. (1973) Narcolepsy in a dog and a cat. J. Am. Vet. Med. Assoc. 162, 1052-1053.
195. Kodama, T., Takahashi, Y. and Honda, Y. (1990) Enhancement of acetylcholine release during paradoxical sleep in the dorsal tegmental field of the cat brain stem. Neurosci. Lett. 114, 277-282.
196. Koran, L. and Raghavan, S. (1993) Fluoxetine for isolated sleep paralysis. Psychomatics 34, 184-187.
197. Kuczenski, R., Segal, D. S., Cho, A. and Melega, W. (1995) Hippocampus norepinephrine, caudate dopamine and serotonine and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J. Neurosci. 15, 1308-1317.
198. Lacey, M. (1993) Neurotransmitter receptors and ionic conductances regulating the activity of neurons in substantia nigra pars compacta and ventral tegmental area. Progr. Brain Res. 99, 251-276.
199. Laffort, F., Mayer, G. and Minz, M. (1994) Modafinal in dirunal sleepiness: A study of 123 patients. Sleep 17, S113-S115.
200. LaGarde, D. (1990) Sustained/continuous operations subgroup of the department of defense human factors engineering technical group: program summary and abstracts from the 9th semiannual meeting. Naval Aerospace Medical Research Lab.: Pensacola, FL.
201. Lammers, G. J., Arends, J., Decierck, A. C., Kamphuisen, H. S. C., Schouwink, G. and Troost, J. (1990) Ritanserin, a serotonin 5-HT antagonist,
202. Lammers, G. J., Arends, J., Declerck, A. C., Ferrari, M. D., Schouwink, G. and Troost, J. (1993) Gamma-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 16, 216-220.
203. 2 receptor blocker, as add-on treatment in narcolepsy. Sleep 14, 130-132.
204. Lammers, G. J. and Van Dijk, J. G. (1992) The mutiple sleep latency test: a paradoxical test?, Clin. Neurol. Neurosurg. 94, S108-S110.
205. Langdon, N., Shindler, J., Parkes, J. D. and Bandak, S. (1986) Fluoxetine in the treatment of cataplexy. Sleep 9, 371-373.
206. Lees, A. J. (1995) Comparison of therapeutic and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Dis. Res. Gp U.K., BMJ 311, 1602-1607.
207. Levender, S. and Sachs, C. (1987) Arousal and personality traits: effects of central stimulants in narcolepsy. Person. Indiv. Diff. 8, 365-370.
208. Lewy, A. J., Sack, R. L., Miller, L. S. and Hoban, T. M. (1987) Antidepressant and circadian phase-shifting effects of light. Science 235, 352-354.
209. Lin, J. S., Roussel, B., Akaoka, H., Fort, P., Debilly, G. and Jouvet, M. (1992) Role of catecholamines in modafinil and amphetamine induced wakefulness, a comparative pharmacological study. Brain Res. 591, 319-326.
210. Lindsley, J. G. (1990) Pharmacological separation between cataplectic atonia and the atonia of REM sleep. Sleep Res. 19, 72.
211. Lock, C. B., Welsh, K. I., Parkes, J. D., Briggs, D. C., Waughan, R. W. and Van Dam, M. (1988) HLA in narcolepsy-cataplexy in the United Kingdom. In: HLA in Narcolepsy, pp. 76-88. Eds Y. Honda and T. Juji. Springer-Verlag: New York.
212. Lucas, E. A., Foutz, A. S., Dement, W. C. and Mitler, M. M. (1979) Sleep cycle organization in narcoleptic and normal dogs. Physiol. Behav. 23,.
213. Lucas E. A., Powell E. W., Murphree O. D. Baseline sleep-wake patterns in the pointer dog. Physiol. Behav. 1977 285-291
214. Luebke, J. I., Greene, R. W., Semba, K., McCarley, R. W., Kamondi, A. and Reiner, P. B. (1992) Serotonin hyperpolarizes cholinergic low threshold burst neurons in the rat laterodorsal tegmental nucleus in vitro. Proc. natn. Acad. Sci. U.S.A. 89, 743-747.
215. Löwenfeld, L. (1902) Uber Narkolepsie. Munch. Med. Wochenschr. 49, 1041-1045.
216. Mack, R. B. (1993) Love potion number 8 1/2. Gamma-hydroxybutyrate poisoning. NC Med. J. 54, 232-233.
217. Mamelak, M., Scharf, M. B. and Woods, M. (1986) Treatment of narcolepsy with y-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 9, 285-289.
218. Matsuki, K., Grumet, F. C., Lin, X., Guilleminault, C. and Dement, W. C. (1992) DQ rather than DR gene marks susceptibility to narcolepsy. Lancet 339, 1052.
219. Matsuki, K., Honda, Y. and Juji, T. (1989) HLA antigens in 206 Japanese patients with narcolepsy and 46 patients with essential Hypersomnia. In: HLA 1991 Vol. 2, pp. 438-440. Eds K. Tsuji, M. Aizawa and T. Sasazuki. Oxford University Press: New York.
220. Matsuki, K., Juji, T. and Honda, Y. (1988) Immunological features of narcolepsy in Japan. In: HLA in Narcolepsy, pp. 150-157. Eds Y. Honda and T. Juji. Springer-Verlag: Berlin.
221. Mayer, G., Meier, E. and Hephata, K. (1995) Selegeline hydrochloride narcolepsy. A double-blind placebo-controlled study. Clin. Neuropharmacol. 18, 306-319.
222. Mayer, G. and Meier-Ewert, K. (1993) Motor dyscontrol in sleep of narcoleptic patients (a life long development?). J. Sleep Res. 2, 143-148.
223. McCarley, R. W. and Hobson, J. A. (1975) Neuronal excitability modulation over the sleep cycle: a structural and mathematical model. Science 189, 58-60.
224. McDaniels, K. (1986) Clinical pharmacology of Monoamine oxidase inhibitors. Clin. Neuropharmacol. 9, 207-234.
225. Mefford, I., Foutz, A., McNerney, V., Mitler, M. and Dement, W. (1982) Distribution of norepinephrine, epinephrine, dopamine, serotonin, 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindole-3-acetic acid in dog brain. Brain Res. 236, 339-349.
226. Meier-Ewert, K., Matsubayashi, K. and Benter, L. (1985) Propranolol: long-term treatment in narcolepsy-cataplexy. Sleep 8, 95-105.
227. Merritt, S. L., Smith, K. M. and Cohen, F. L. (1990) Narcolepsy and depressive symptomatology. Sleep Res. 19, 169.
228. Mesulam, M. M., Ufson, E. J., Wainer, B. H. and Levey, A. I. (1983) Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-6). Neuroscience 10, 1185-1201.
229. Mignot, E., Guilleminault, C., Bowersox, S., Fruhstorfer, B., Nishino, S., Maddaluno, J., Ciaranello, R. and Dement, W. C. (1989) Central alpha-1 adrenoceptor subtypes in narcolepsy-cataplexy: a disorder of REM sleep. Brain Res. 490, 186-191.
230. Mignot, E., Guilleminault, C., Bowersox, S., Rappaport, A. and Dement, W. C. (1988a) Effect of alpha 1 adrenoceptors blockage with prazosin in canine narcolepsy. Brain Res. 444, 184-188.
231. Mignot, E., Guilleminault, C., Bowersox, S., Rappaport, A. and Dement, W. C. (1988b) A role of central alpha-1 adrenoceptors in canine narcolepsy. J. Clin. Invest. 82, 885-894.
232. Mignot, E., Guilleminault, C., Grumet, F. C. and Dement, W. C. (1992) Is narcolepsy an autoimmune disease? In: Proc. Third Milano Intl Symp. 18-19 September: Sleep, Hormones, and the Immune System, pp. 29-38. Eds S. Smirne, M. Francesci, L. Ferini-Strambi and M. Zucconi. Masson: Milan.
233. Mignot, E., Hayduck, R., Black, J., Grumet, F.C., Guilleminault, C. and the U.S. Modifinal Narcolepsy Study Group (1997) HLA class II studies in 509 narcoleptic patients. Sleep Res. 26 (in press).
234. Mignot, E., Kimura, A., Latterman, A., Lin, X., Yasuraga, S., Mueller, G., Eckhardt, Ratazzi, C., Lin, L., Guilleminault, C., Dement, W.C. and Underhill, P. Extensive HLA class II studies in 58 non DRBI 15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens 49 (in press).
235. Mignot, E., Laude, D., Elghozi, J. L., Le Quan-Bui, K. H. and Meyer, P. (1982) Central administration of yohimbine increases free 3-methoxy-4-hydroxyphenylethylenglycol in the CSF of the rat. Eur. J. Pharmacol. 83, 135-138.
236. Mignot, E., Lin, X., Arrigoni, J., Macaubas, C., Olive, F., Hallmeyer, J., Undershill, P., Guilleminault, C., Dement, W. C. and Grumet, F. C. (1994a) DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 17, S60-S67.
237. Mignot, E., Nishino, S., Guilleminault, C. and Dement, W. C. (1994b) Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 17, 436-437.
238. Mignot, E., Nishino, S., Hunt Sharp, L. E., Arrigoni, J., Siegel, J. M., Reid, M. S., Edgar, D. M., Ciaranello, R. D. and Dement, W. C. (1993a) Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J. Neurosci. 13, 1057-1064.
239. Mignot, E., Renaud, A., Nishino, S., Arrigoni, J., Guilleminault, C. and Dement, W. C. (1993b) Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology 113, 76-82.
240. Mignot, E., Tafti, M., Dement, W. C. and Grumet, F. C. (1995) Narcolepsy and Immunity. Adv. Neuroimmunol. 5, 23-37.
241. Mignot, E., Wang, C., Rattazzi, C., Gaiser, C., Lovett, M., Guilleminault, C., Dement, W. C. and Grumet, C. (1991) Genetic linkage of autosomal recessive canine narcolepsy with an immunoglobulin μ chain switch-like segment. Proc. natn. Acad. Sci. U.S.A. 88, 3475-3478.
242. Mitler, J. D., Farber, J., Gatz, P., Roffwarg, H. and German, D. C. (1983) Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and waking in the rat. Brain Res. 273, 133-141.
243. Mirenowicz, J. and Schultz, W. (1996) Preferential activation of midbrain dopamine neurons by appetitive rather than aversive stimuli. Nature 379, 449-451.
244. Mitler, M., Boysen, M., Campbell, L. and Dement, W. C. (1974) Narcolepsy-cataplexy in a female dog. Exp. Neurol. 45, 332-340.
245. Mitler, M. and Dement, W. C. (1974) Cataplexy-like behavior in cats after microinjection of carbachol in pontine reticular formation. Brain Res. 68, 335-343.
246. Mitler, M. M. (1994) Evaluation of treatment efficacy in narcolepsy. Sleep 17, S103-S106.
247. Mitler, M. M., Aldrich, M. S., Koob, G. F. and Zarcone, V. P. (1994) Narcolepsy and its treatment with stimulants. Sleep 17, 352-371.
248. Mitler, M. M. and Dement, W. C. (1977) Sleep studies on canine narcolepsy: pattern and cycle comparisons between affected and normal dogs. Electroencephalogr. Clin. Neurophysiol. 43, 691-699.
249. Mitler, M. M., Erman, M. and Hajdukovic, R. (1993a) The treatment of excessive somnolence with stimulant drugs. Sleep 16, 203-206.
250. Mitler, M. M., Gujavarty, K. S. and Browman, C. P. (1982) Maintenance of wakefulness test: a polysomnographic technique for evaluating treatment in patients with excessive somnolence. Electroenchephalogr. Clin. Neurophysiol. 53, 658-661.
251. Mitler, M. M. and Hajdukovic, R. (1991) Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 14, 218-220.
252. Mitler, M. M., Hajdukovic, R. and Erman, M. (1993b) The treatment of narcolepsy with methamphetamine. Sleep 16, 306-317.
253. Mitler, M. M., Hajdukovic, R., Erman, M. and Koziol, J. A. (1990) Narcolepsy. J. Clin. Neurophysiol. 7, 93-118.
254. Mitler, M. M., Hajukovic, R. and Erman, M. (1992) Methamphetamine normalizes sleepiness and performance in narcoleptics. Sleep Res. 21, 235.
255. Mitler, M. M., Shafor, R., Hajdukovich, R., Timms, R. M. and Browman, C. P. (1986) Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 9, 260-264.
256. Mitler, M. M., Soave, O. and Dement, W. C. (1976) Narcolepsy in seven dogs. J. Am. Vet. Med. Assoc. 168, 1036-1038.
257. Monti, J. (1982) Catecholamines and the sleep wake cycle. I. EEG and behavioral arousal. Life Sci. 30, 1145-1157.
258. 1A receptor agonist 8-OH-DPAT on sleep and wakefulness in the rat. J. Sleep Res. 1, 169-175.
259. Monti, J., Pineyro, G., Orellana, C., Boussard, M., Jantos, H., Labraga, P., Olivera, S. and Alvarino, F. (1990) 5-HT receptor agonists 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and 8-OH-DPAT increase wakefulness in the rat. Biogen. Amines 7, 145-151.
260. Montplaisir, J., Billard, M., Takahashi, S., Bell, I. R., Guilleminault, C. and Dement, W. C. (1978) Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol. Psychiat. 13, 78-89.
261. Montplaisir, J. and Godbout, R. (1986) Serotonergic reuptake mechanisms in the control of cataplexy. Sleep 9, 280-284.
262. Montplaisir, J. and Poirier, G. (1988) HLA in disorders of excessive somnolence without cataplexy. In: HLA in Narcolepsy, pp. 186-190. Eds Y. Honda and T. Juji. Springer-Verlag: New York.
263. Morton, W., Sonne, S. and Verga, M. (1995) Venlafaxine: a structurally unique and novel antidepressant. Ann. Pharmacother. 29, 387-395.
264. Moscovitch, A., Partinen, M. and Guilleminault, C. (1993) The positive diagnosis of narcolepsy and narcolepsy's borderland. Neurology 43, 55-60.
265. Mosko, S. S., Shampain, D. S. and Sassin, J. F. (1984) Nocturnal REM latency and sleep disturbance in narcolepsy. Sleep 7, 115-125.
266. Mouret, J., Sanchez, P., Taillard, J., Lemoine, P., Robelin, N. and Canini, F. (1988) Treatment of narcolepsy with L-tyrosine. Lancet Dec 24/31, 1458-1459.
267. Mullington, J. and Broughton, R. (1993) Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 16, 444-456.
268. Navelet, Y., Anders, T. and Guilleminault, C. (1976) Narcolepsy in children. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 171-177. Eds C. Guilleminault, W. C. Dement and P. Passouant. Spectrum Publications: New York.
269. Nicholson, A. N. and Pascoe, P. A. (1990) Dopaminergic transmission and the sleep-wakefulness continuum in man. Neuropharmacology 29, 411-417.
270. Nicoll, R. A. (1977) Excitatory action of TRH on spinal motoneuorons. Nature 265, 242-243.
271. Nishino, S. (1997) Neuropharmacology of canine narcolepsy. In: Narcolepsy Update 1994. Springer Verlag: Heidelberg (in press).
272. Nishino, S., Mignot, E., Fruhstorfer, B., Ueno, R., Kilduff, T. S., Hayaishi, O., Dement, W.C. (1990a) Effects of intravenous administration of PGs on narcoleptic dogs. In: Endogenous Sleep Factors, pp. 77-83. Eds. S. Inoué and J.M. Kruger. Banma Text: Wassenaar, The Netherlands.
273. Nishino, S., Haak, L., Shepherd, H., Guilleminault, C., Sakai, T., Dement, W. C. and Mignot, E. (1990b) Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep. J. Pharmacol. Expl Ther. 253, 1145-1152.
274. Nishino, S., Mignot, E., Fruhstorfer, B., Kilduff, T. S., Ueno, R., Hayaishi, O. and Dement, W. C. (1990c) Effects of intravenous administration of prostaglandins on canine narcolepsy. In: Endogenous Sleep Factors, pp. 77-83. Eds S. Inoue and J. M. Krueger. SPB Academic Publishing: The Hague.
275. Nishino, S., Arrigoni, J., Fruhstorfer, B., Shelton, J., Dement, W. C. and Mignot, E. (1992) Effects of chronic administration of yohimbine (alpha-2 antagonist) on cataplexy and platelet alpha-2 receptors of narcoleptic canines. Sleep Res. 21, 66.
276. Nishino, S., Arrigoni, A., Shelton, J., Dement, W. C. and Mignot, E. (1993a) Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 16, 706-712.
277. Nishino, S., Arrigoni, J., Dement, W. C. and Mignot, E. (1991a) Effect of L-threo-DOPS on canine narcolepsy. Sleep 20, 72.
278. Nishino, S., Arrigoni, J., Kanbayashi, T., Dement, W. C. and Mignot, E. (1996a) Comparative effects of MAO-a and MAO-b selective inhibitors on canine cataplexy. Sleep Res. 25, 315.
279. Nishino, S., Arrigoni, J., Kanbayashi, T., Sampathkumaran, R., Tafti, A., Dement, W. C. and Mignot, E. (1995a) TRH and its analogs significantly reduce canine cataplexy. Sleep Res. 24A, 352.
280. Nishino, S., Arrigoni, J., Valtier, D., Miller, J. D., Guilleminault, C., Dement, W. C. and Mignot, E. (1991b) Dopamine D2 mechanisms in canine narcolepsy. J. Neurosci. 11, 2666-2671.
281. Nishino, S., Fruhstorfer, B., Arrigoni, J., Guilleminault, C., Dement, W. C. and Mignot, E. (1993b) Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J. Pharmacol. Expl Ther. 264, 1079-1084.
282. Nishino, S., Mao, J., Sampathkumaran, R., Honda, K., Dement, W. C. and Mignot, E. (1996b) Differential effects of dopaminergic and noradrenergic uptake inhibitors on EEG arousal and cataplexy of narcoleptic canines. Sleep Res. 25, 317.
283. Nishino, S., Mignot, E. and Dement, W. C. (1994a) Sedativehypnotics. In: Textbook of Psychopharmacology, pp. 405-416. Eds A. F. Schatzberg and C. B. Nemeroff. American Psychiatric Press: Washington, DC.
284. Nishino, S., Reid, M., Dement, W. C. and Mignot, E. (1994b) Neuropharmacology and neurochemistry of canine narcolepsy. Sleep 17, S84-S92.
285. Nishino, S., Sampathkumaran, R., Tafti, M. and Mignot, E. (1995b) Ambulatory rest-activity monitoring in narcoleptic and control dogs. Sleep Res. 24, 309.
286. A agonists and antagonists on canine cataplexy. J. Pharmacol. Expl Ther. 272, 1170-1175.
287. Nishino, S., Tafti, M., Reid, M. S., Shelton, J., Siegel, J. M., Dement, W. C. and Mignot, E. (1995c) Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of narcolepsy. J. Neurosci. 15, 4806-4814.
288. Nomikos, G. G., Damsma, G., Wenkstern, D. and Fibger, H. C. (1990) In vivo charcterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 6, 106-112.
289. Ohayon, M. M., Priest, R. G., Caulet, M. and Guiileminault, C. G. (1996) Hypnagogic and hypnopompic hallucinations: pathological phenomena?. Br. J. Pharmacol. 169, 459-467.
290. Ono, H. and Fukuda, H. (1982) Ventral root depolarization and spinal reflex augmentaion by a TRH analog in rat spinal cord. Neuropharmacology 21, 739-744.
291. Onofrj, M., Curatola, L., Ferracci, F. and Fulgente, T. (1992) Narcolepsy associated with primary temporal lobe B-cells lymphoma in a HLA DR2 negative subject. J. Neurol. Neurosurg. Psychiat. 55, 853-853.
292. Papez, J. W. (1937) A proposed mechanism of emotion. Arch. Neurol. Psychiat. 38, 725-743.
293. Parkes, J.D. (1976) Amphetamines and alertness. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 643-658. Eds C. Guilleminault, W. C. Dement and P. Passouant. Spectrum Publications: New York.
294. Parkes, J.D. (1985a) Amphetamines and other drugs. In: Sleep and its Disorders, pp. 459-482. W.B. Saunders Co.: London.
295. Parkes, J. D. (1985b) Daytime Drowsiness. W.B. Saunders: London.
296. Parkes, J. D. (1990) Central nervous system stimulant drugs. In: Handbook of Sleep Disorders, pp. 755-778. Ed. M. Thorpy. Marcel Dekker, Inc.: New York.
297. Parkes, J. D., Baraitser, M., Marsden, C. D. and Asselman, P. (1975) Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol. Scand. 52, 337-353.
298. Parkes, J. D. and Dahlitz, M. (1993) Amphetamine prescription. Sleep 16, 201-203.
299. Parkes, J. D., Fenton, G., Struthers, G., Curzon, G., Kantamaneni, B. D., Buxton, B. H. and Record, C. (1974) Narcolepsy and Cataplexy. Clinical features, treatment and cerebrospinal fluid findings. Q. J. Med. 172, 525-536.
300. Parkes, J. D. and Fenton, G. W. (1973) Levo(-) amphetamine and dextro (+) amphetamine in the treatment of narcolepsy. J. Neurol. Neurosurg. Psychiat. 36, 1076-1081.
301. Pasi, A., Wettstein, A., Foletta, D. and Gramsch, C. (1982) Idiopathic narcolepsy: effects of naloxone studied in one of three patients with unelevated beta-endorphin-like immunoreactivity plasma levels. J. Clin. Psychopharmacol. 2, 216-217.
302. Passouant, P. (1974) REM's ultradian rhythm during 24 hours in narcolepsy. In: Chronobiology, pp. 494-498. Eds L. E. Scheving, F. Halberg and J. E. Pauly. Igaku Shoin Ltd: Tokyo.
303. Passouant, P. and Billiard, M. (1976) The evolution of narcolepsy with age. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 179-186. Eds C. Guilleminault, W. C. Dement and P. Passouant. Spectrum Publications: New York.
304. Patsusak, A., Schick-Boschetto, B., Zuber, C., Feldkamp, M., Pinelli, M., Sihn, S., Donnefeld, A., McCormack, M., Leen-Mitchel, M. and Woodland, C. (1993) Pregancy outcome following first-trimester exposure to fluoxetine (prozac). JAMA 269, 2246-2248.
305. Paty, J., Cugy, D. and Morault, P. (1995) L-Tyrosine in narcolepsy-cataplexy. Sleep Res. 24A, 144.
306. Paulus, W., Homberg, V. and Noth, J. (1983) Cataplexy relieved by tiapride. Arch. Neurol. 40, 828.
307. Pawluk, L. K., Hurwitz, T. D., Schulter, J. L., Ullewig, C. and Mahowald, M. W. (1995) Psychiatric morbidity in narcoleptics on chronic high doses methylphenidate therapy. J. Nerv. Ment. Dis. 183, 45-48.
308. Peet, M. and Coppen, A. (1979) The pharmacokinetics of antidepressant drugs: relevance to their therapeutic effect. In: Psychopharmacology of Affective Disorders, pp. 91-107. Eds E. S. Paykel and A. Coppen. Oxford University Press: Oxford.
309. Plazzi, G., Montagna, P., Provini, F., Bizzi, A., Cohen, M. and Lugaresi, E. (1996) Pontine lesions in idiopathic narcolepsy. Neurology 46, 1250-1254.
310. Poceta, J. S., Hajdukovic, R. and Mitler, M. M. (1994) Improvement in cataplexy with yohimbine and paroxetine: case report. Sleep Res. 23, 304.
311. Pollack, C. P. and Green, J. (1990) Eating and its relationships with subjective alertness and sleep in narcoleptic subjects living without temporal clues. Sleep 13, 467-478.
312. Pons, G., Rey, E. and Matheson, I. (1994) Excretion of psychoactive drugs in breat milk: pharmacokinetic principles and recommendations. Clin. Pharmacokinet. 27, 270-289.
313. Potter, W. Z., Manji, H. and Rudorfer, M. V. (1994) Tricyclics and tetrcyclics. In: Textbook of Psychopharmacology, pp. 141-160. Eds A. F. Schatzberg and C. B. Nemeroff. American Psychiatric Press: Washington, DC.
314. Poulson, E. and Robson, J. M. (1964) Effect of phenelzine and some related compounds in pregancy. J. Endocrinol. 30, 205-215.
315. Prange, A., Wilson, I., Lara, P., Alltop, L. and Breese, G. (1972) Effects of thyrotropin-releasing hormone in depression. Lancet 2(785), 999-1002.
316. Price, P. A., Scachter, M., Smith, S. J., Baxter, R. C. H. and Prakes, J. D. (1981) γ-Hydroxybutylate in narcolepsy. Ann. Neurol. 9, 198.
317. Prinzmetal, M. and Bloomberg, W. (1935) The use of benzedrine for the treatment of narcolepsy. JAMA 105, 2051-2054.
318. Prusinski, A. and Szulc-Kuberska, J. (1973) Karbamizepina w leczeniu narkolkepsji. Pglski Tysob. Lekar. 32, 1244-1245.
319. Putkonen, P. and Bergström, L. (1980) Clonidine alleviated cataplectic symptoms in narcolepsy. In: Sleep, pp. 414-416. Ed. W. P. Koella. Karger: Basel.
320. Quattrochi, J. J., Mamelak, A., Binder, D. K., Williams, J., Rittenhouse, C. and Hobson, J. A. (1992) Dynamic suppression of REM sleep by parenteral administration of the serotonin-1 agonist eltoparazine. Sleep 15, 125-132.
321. Ranga, K. and Krishnan, R. (1994) Monoamine oxidase inhibitors. In: Textbook of Psychopharmacology, pp. 183-193. Eds A. F. Schatzberg and C. B. Nemeroff. American Psychiatric Press: Washington, DC.
322. Rani, R., Fernandez-Vina, M., Zaheer, S., Beena, K. and Stastny, P. (1993) Study of HLA class II alleles by PCR oligotyping in leprosy patients from north India. Tissue Antig. 42, 133-137.
323. Raynal, D. (1976) Polygraphic aspects of narcolepsy. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 669-684. Eds C. Guilleminault, W. C. Dement and P. Passouant. Spectrum Publications: Inc., New York.
324. Rechtschffen, A., Wolpert, E. A., Dement, W. C., Mitchell, S. A. and Fisher, C. (1963) Noctural sleep of narcoleptics. Electroencephalogr. Clin. Neurophysiol. 15, 599-609.
325. Redlich, E. (1915) Zur narkolepsie frage. Mschr. Psychiat. Neurol. 37, 85.
326. Reid, M. S., Geary, J. n., Siegel, J. M., Dement, W. C. and Mignot, E. (1993) Modulation of cataplexy in the narcoleptic canines by local infusion of monoaminergic compounds. Sleep Res. 22, 17.
327. Reid, M. S., Nishino, S., Shelton, J., Arrigoni, J., Geary, W., Dement, W. C. and Mignot, E. (1994a) Evidence for excessive daytime sleepiness in narcoleptic Dobermann pinschers. Sleep Res. 23, 309.
328. Reid, M. S., Siegel, J. M., Dement, W. C. and Mignot, E. (1994b) Cholinergic mechanisms in canine narcolepsy: II. Acetylcholine release in the potine reticular formation is enhanced during cataplexy. Neuroscience 59, 523-530.
329. Reid, M. S., Tafti, M., Geary, J., Nishino, S., Siegel, J. M., Dement, W. C. and Mignot, E. (1994c) Cholinergic mechanisms in canine narcolepsy: I. Modulation of cataplexy via local drug administration into pontine reticular formation. Neuroscience 59, 511-522.
330. Reid, M. S., Tafti, M., Nishino, S., Sampathkumaran, R., Siegel, J. M., Dement, W. C. and Mignot, E. (1996) Local administration of dopaminergic drugs into the ventral tegmental area modulate cataplexy in the narcoleptic canine. Brain Res. 733, 83-100.
331. Reid, M. S., Tafti, M., Nishino, S., Siegel, J. M., Dement, W. C. and Mignot, E. (1994d) Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors. Sleep 17, 424-435.
332. Reinish, L. W., McFarlane, J. G., Sandor, P. and Shapiro, C. M. (1995) REM changes in narcolepsy with selegiline. Sleep 18, 362-367.
333. Renaud, A., Nishino, S., Dement, W. C., Guilleminault, C. and Mignot, E. (1991) Effect of SDZ NVI-085, a putative subtype selective alpha-1 agonist on canine cataplexy. Eur. J. Pharmacol. 205,. Renaud, A., Nishino, S., Valtier, D., Guilleminault, C., Dement, W. C. and Mignot, E. (1990) Effects of buspirone on canine cataplexy. In: 10th Congress of ESRS, pp. 249.
334. Renaud, A., Nishino, S., Dement, W. C., Guilleminault, C. and Mignot, E. (1991) Effect of SDZ NVI-085, a putative subtype selective alpha-1 agonist on canine cataplexy. Eur. J. Pharmacol. 205,. Renaud, A., Nishino, S., Valtier, D., Guilleminault, C., Dement, W. C. and Mignot, E. (1990) Effects of buspirone on canine cataplexy. In: 10th Congress of ESRS, pp. 249.
335. Reynolds, G. P., Elsworth, J. D., Blau, K., Sandler, M., Lees, A. J. and Stern, G. M. (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 6, 542-544.
336. Ribstein, M. (1976) Hypnagogic hallucinations. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 145-160. Eds C. Guilleminault, W. C. Dement and P. Passouant. Spectrum Publications: New York.
337. Richardson, R. T. and Delang, M. R. (1991) Electrical studies of the function of the nucleus basalis in primates. In: The Basal Forebrain: Anatomy to Function, pp. 233-252. Eds. P. W. Napier, P. W. Kalivas and I. Hanin. Plenum Press: New York.
338. Richelson, E. and Pfenning, M. (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectivity block norepinephrine uptake. Eur. J. Pharmacol. 104, 277-286.
339. Riederer, P., Konradi, C., Hebenstreit, G. and Youdim, M. (1989) Neurochemical perspectives to the function of monamine oxidase. Acta Neurol. Scand. 126, 41-45.
340. Roehrs, T., Zorick, F. R. W., Paxton, C., Sicklesteel, J. and Roth, T. (1986) Alerting effects of naps in patients with narcolepsy. Sleep 9, 194-199.
341. Rogers, A. E. (1984) Problems and coping strategies identified by narcoleptic patients. J. Neurosurg. Nursing 16, 326-334.
342. Rogers, A. E., Aldrich, M. S., Berrios, A. M. and Rosenberg, R. S. (1997) Compliance with stimulant medications in patients with Narcolepsy. Sleep (in press).
343. Rogers, A. E., Aldrich, M. S. and Caruso, C. C. (1994) Patterns of sleep and wakefulness in treated narcoleptic subjects. Sleep 17, 590-597.
344. Rogers, A. E., Mehan, J., Guilleminault, C., Grumet, F. C. and Mignot, E. HLA DR2 and DQB1*0602 Typing studies in 188 narcoleptic patients with cataplexy. Neurology 48 (in press).
345. Rogers, A. E. and Rosenberg, R. S. (1990) Test of memory in narcoleptics. Sleep 13, 42-52.
346. Rolls, E. T., Sanghera, M. K. and Roper-Hall, A. (1979) The latency of activation of neurones in the lateral hypothalamus and substantia innominata during feeding in the monkey. Brain Res. 164, 121-135.
347. Roselaar, S. E., Langdon, N., Lock, C. B., Jenner, P. and Parkes, J. D. (1987) Selegiline in narcolepsy. Sleep 10, 491-495.
348. Rosenthal, C. (1939) Uber das aufreten von halluzinatorischkataplektischem angstsyndrom, wachanfallen und ahnlichen Storungen bei schizophrenen. Mschr. Psychiat. 102, 11.
349. Rosenthal, L., Roehrs, T. A., Hayashi, H., Zorick, F. J., Wittig, R. M., Rosenthal, J. and Roth, T. (1991) HLA DR2 in narcolepsy with sleep-onset REM periods but not cataplexy. Biol. Psychiat. 30, 830-836.
350. Rosenthal, L., Zorick, F., Merlotti, L., Wittig, R., Roehrs, T. and Roth, T. (1990) Signs and symptoms associated with cataplexy in narcoleptic patients. Biol. Psychiat. 27, 1057-1060.
351. 3H]-noradrenaline in homogenates from rat hypothalamus. Biochem. Pharmacol. 28, 1085-1088.
352. Roth, B. (1962) Narkolepsie und Hypersomnie. VEB Verlag Volk und Gesundheit: Berlin.
353. Roth, B. (1980) Narcolepsy and Hypersomnia. Karger: Basel.
354. Roth, B., Bruhova, S. and Lehovsky, M. (1969) REM sleep and NREM sleep in narcolepsy and hypersomnia. Electroencephalog. Clin. Neurophysiol. 26, 176-182.
355. Roth, B. and Nevsimalova, S. (1975) Depression in narcolepsy and hypersomnia. Schweitz. Arch. Neurol. Neurochir. Psychiat. 116, 291-300.
356. Roth, B., Nevsimalova, S., Sonka, K. and Docekal, P. (1986) An alternative to the multiple sleep latency test to determine sleepiness in narcolepsy and hypersomnia: Polygraphic scores of sleepiness. Sleep 9, 243-245.
357. Roth, B., Bruthova, S. and Perkova, L. (1968) Familial sleep paralysis. Archiv. Neurol. Neurch. Psychiat. 102, 321-330.
358. Royant-Parola, S. (1992) Narcolepsy and the psychiatric tableau. A specific form of narcolepsy. Ann. Med.-Psychol. 150, 286-290.
359. Ryan, L. J., Linder, J. C., Martone, M. E. and Groves, P. M. (1990) Histological and ultrastructural evidence that D-amphetamine causes degeneration in neostriatum and frontal cortex of rats. Brain Res. 518, 67-77.
360. Sachs, C. and Levander, S. (1981) Personality traits in patients with narcolepsy. Person. Indiv. Diff. 2, 319-324.
361. Sakai, K., El Mansari, M., Lin, J. G., Zhang, J. G. and Vanni-Mercier, G. (1990) The posterior hypothalamus in the regulation of wakefulness and paradoxical sleep. In: The Diencephalon and Sleep, pp. 171-198. Eds M. Mancia and G. Marini. Raven Press: New York.
362. Salín-Pascual, R. and de la Fuente, J. R. (1985) Effect of clonidine on narcolepsy. J. Clin. Psychiat. 46, 528-531.
363. Sampaio, E. P., Kaplan, G. and Miranda, A. (1993) The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168, 1146-1150.
364. Sandyk, R and Gillman, M. A. (1985a) Efficacy of trazodone in narcolepsy. Eur. Neurol. 24, 335-337.
365. Sandyk, R. and Gillman, M. A. (1985b) Naloxone ameliorates narcolepsy. Clin. Neuropharmacol. 358, 96-97.
366. Sandyk, R. and Gillman, M. A. (1985c) Nomifensine exacerbates narcolepsy. Neurology 35, 138-139.
367. Sarkadi, A., Szabo, S., Laszy, J., Ambrus, A. and Szporny, L. (1988) Effects of thyrotropin-releasing hormone and its analogue L-6-ketopiperidine-2-carbonyl-leucyl-L-proline-amide on behaviour and electroencephalogram. Arzneimittelforschung 38, 1134-1138.
368. Scally, M. C., Ulus, I. and Wurtman, R. J. (1977) Brain tyrosine level controls striatal dopamine synthesis in haloperidol-treated rats. J. Neural Transm. 34, 79-91.
369. Schachter, M. and Parkes, J. D. (1980) Fluvoxamine and clomipramine in the treatment of cataplexy. J. Neurol. Neurosurg. Psychiat. 43, 171-174.
370. Schacther, M., Price, P. A. and Parkes, J. D. (1979) Deprenyl in narcolepsy. Lancet, 831-832.
371. Scharf, M. B., Brown, D., Woods, M., Brown, L. and Hirschowitz, J. (1985) The effects and effectiveness of gammahydroxybutyrate in patients with narcolepsy. J. Clin. Psychiat. 46, 222-225.
372. Scharf, M. B. and Fletcher, K. (1988) Rebound cataplexy; a complication of drug withdrawal in narcolepsy. Sleep Res. 17, 246.
373. Schenck, C. H. and Mahowald, M. W. (1992) Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann. Neurol. 32, 3-10.
374. Scherschlicht, R., Pole, P., Schneeberger, J., Steiner, M. and Haefely, W. (1982) Selective supression of rapid eye movement sleep (REMS) in cats by typical and atypical antidepressants. In: Typical and Atypical Antidepressants: Molecular Mechanisms. Eds E. Costa and G. Racagni. Raven Press: New York.
375. Schmidt, H., Clark, R. and Hyman, R. (1977) Protriptyline: an effective agent in the treatment of Narcolepsy-cataplexy syndrome and hypersomnia. Am. J. Psychiat. 134, 183-185.
376. Schneeberger, P. J. and Haefely, W. (1979) Effects of several centrally active drugs on the sleep-wakefulness cycle of cats. Neuropharmacology 18, 259-267.
377. Schrader, G. and Hicks, P. (1984) Narcolepsy, paranoid psychosis, major depression and Tardive dyskinesia. J. Nerv. Ment. Dis. 172, 439-441.
378. Schrader, H., Bendixen-Markset, A. C. and Treidene, H. E. (1986) The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol. Scand. 74, 297-303.
379. Scrima, L., Hartman, P. G., Johnson, F. H. and Hiller, F. C. (1989) Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol. Psychiat. 26, 331-343.
380. Scrima, L., Hartman, P. G., Johnson, F. H., Thomas, E. E. and Hiller, F. C. (1990oa) The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep 13, 479-490.
381. Scrima, L., Johnson, F. H., Thomas, E. G. and Hiller, E. E. (1990b) The effects of gamma-hydroxybutyrate (GHB) on multiple sleep latency test (MSLT) in narcolepsy patients; a long term study. Sleep Res. 19, 288.
382. Seijun, T. (1970) Metamphetamine psychosis. In: Current Concept on Amphetamine Abuse, pp. 159-161. Eds E. H. Ellinwood and S. Cohen. National Institute of Mental Health: Rockville, MD.
383. Servan, J., Marchsand, F., Garma, L., Seihean, D., Hauw, J. J. and Delattre, J. Y. (1995) Symptomatic narcolepsy: an anatomical study. Sleep Res. 24, 345.
384. Shapiro, W. R. (1975) Treatment of cataplexy with clomipramine. Arch. Neural. 32, 653-656.
385. Shelton, J., Nishino, S., Vaught, J., Dement, W. C. and Mignot, E. (1995) Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 18, 817-826.
386. Shoham, S., Davenne, D. and Cady, A. B. (1987) Recombinant tumor necrosis factor and interleukin 1 enchance slow-wave sleep. Am. J. Physiol. 253, R142-149.
387. Shute, C. C. D. and Lewis, P. R. (1967) The ascending cholinergic reticular system: neocortical, olfactory and subcortical projections. Brain 90, 497.
388. Sidvena, L., Babichev, V., Airapetyants, M., Kolmeiteiseva, I., Shvachkin, Y. and Simirnova, A. (1988) Effect of the thyrotropin-releasing hormone analogue on an electroencephalographic picture of sleep. Neurosci. Behav. Physiol. 18, 282-286.
389. Siegel, J. M. (1994) Brainstem mechanisms generating REM sleep. In: Principles and Practice of Sleep Medicine, pp. 125-144. Eds M. H. Kryger, T. Roth and W. C. Dement. W. B. Saunders Co.: Philadelphia, PA.
390. Siegel, J. M., Nienhuis, R., Fahringer, H., Paul, R., Shiromani, P., Dement, W. C., Mignot, E. and Chiu, C. (1991) Neuronal activity in narcolepsy: identifiction of cataplexy related cells in the medial medulla. Science 262, 1315-1318.
391. Siegel, J. M., Nienhuis, R., Fahringer, H. M., Chiu, C., Dement, W. C., Mignot, E. and Lufkin, R. (1992) Activity of medial mesopontine units during cataplexy and sleep-waking states in the narcoleptic dog. J. Neurosci. 13, 1640-1646.
392. Simon, R. P., Gherson, M. D. and Brooks, D. C. (1973) The role of the raphe nuclei in the regulation of pontogeniculate-occipital wave activity. Brain
393. Simpson, L. L. (1976) The effect of behavioral stimulant doses of amphetamine on blood pressure. Arch. Gen. Psychiat. 33, 691-695.
394. Simpson, L. L. (1978) Blood pressure and heart rate responses produced by D-amphetamine: correlation with blood levels of drug. J. Pharmcol. Expl Ther. 205, 366-373.
395. Sitaram, N., Mendelson, W. B., Wyatt, R. D. and Gillin, J. C. (1977) The time-dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep. Brain Res. 122, 562-567.
396. Sitaram, N., Moore, A. M. and Gillin, J. C. (1978) Induction and resetting of REM sleep rhythm in normal man by arecholine: blockade by scopolamine. Sleep 1, 83-90.
397. Sitaram, N., Wyatt, R. J., Dawson, S. and Gillin, J. C. (1976) REM sleep induction by physostigmine infusion during sleep. Science 191, 1281-1283.
398. Smith, M., Parkes, J. and Dahlitz, M. (1996) Venlafaxine in the treatment of the narcoleptic syndrome. J. Sleep Res. 5, 217.
399. Sobue, I., Takayanagi, T., Nakanishi, T., Tsubaki, T., Uono, M., Kinoshita, M., Igata, A., Miyazaki, M., Yoshida, M., Ando, K., Maruyama, S., Mitsuma, T., Nihei, N., Sakuma, A. and Kato, K. (1983) Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J. Neural. Sci. 61, 235-248.
400. Soldatos, C. R., Kales, A. and Cadieux, R. J. (1983) Treatment of sleep disorders II. Narcolepsy. Rational Drug Ther. 17, 1-7.
401. Sonka, K., Roth, B. and Posmurova, M. (1989) The effect of naloxone on the symptoms of narcolepsy. Agressotogie 30, 93-96.
402. Sonka, K., Roth, B. and Posmurova, M. (1990) Small doses of naltrexon in narcolepsy. In: 10th Congress of the European Sleep Research Society, pp. 253. Strasbourg.
403. Sonka, K., Tafti, M. and Billiard, M. (1991) Narcolepsy and Ageing. In: Sleep and Ageing, pp. 181-186. Eds S. Smirne, M. Franceschi and L. Ferini-Strambi. Masson Press: Milan.
404. Sours, J. A. (1963) Narcolepsy and other disturbances in the sleep-walking rhythm: a study of 115 cases with review of the literature. J. Nerv. Ment. Dis. 137, 525-542.
405. Steiner, E., Villen, T., Hallberg, M. and Rane, A. (1984) Ampehtamine secretion in breast milk. Eur. J. Clin. Pharmacol. 27, 123-124.
406. Steinfels, G. F., Heym, J., Strecker, R. E. and Jacobs, B. L. (1983) Response of dopaminergic neurons in cat to auditory stimuli presented across the sleep-waking cycle. Brain Res. 277, 150-154.
407. Steriade, M., Datta, S. D. P., Oakson, G. and Curró Dossi, R. (1990) Neuronal activities in brain-stem cholinergic nuclei related to tonic activation processes in thalamocortical systems. J. Neurosci. 10, 2541-2559.
408. Steriade, M. and McCarley, R. W. (1990) Brainstem Control of Wakefulness and Sleep. Plenum Press: New York.
409. Stoohs, R., Mignot, E., Suh, B., Norriani, B. and Guilleminault, C. (1990a) L-Tyrosine does not improve sleepiness in narcolepsy. In: 10th Congress of the European Sleep Research Society, pp. 257. Strasbourg.
410. Stoohs, R., Mignot, E., Suh, B., Norriani, B. and Guilleminault, C. (1990b) Yohimbine-HCL does not improve narcolepsy. In: 10th Congress of the European Sleep Research Society, pp. 256. Strasbourg.
411. Stowe, Z. and Nemeroff, C. (1995) Psychopharmacology during pregancy and lactation. In: The American Psychiatry Press Textbook of Psychopharmacology, pp. 823-837. Eds A. Schatzberg and C. B. Nemeroff. American Psychiatric Press: Washington, DC.
412. Sugerman, J. L. and Welsh, J. K. (1989) Physiological sleep tendency and ability to maintain alertness at night. Sleep 12, 106-112.
413. Sulser, F. and Mobley, P. L. (1980) Biochemical effects of antidepressants in animals. In: Psychotropic Agent: Antipshychotics and Antidepressants, Handbook of Experimental Pharmacolgy Vol. 55, Part I, pp. 471-490. Eds F. Hoffmeister and G. Stille. Springer-Verlag: Berlin.
414. Tafti, M., Nishino, S., Dement, W. C. and Mignot, E. (1995) Narcolepsy is associated with increased microglia expression of MHC class II molecules. Sleep Res. 24A, 372.
415. Tafti, M., Villemin, E., Carlander, B., Besset, A. and Biliard, M. (1992) Sleep onset rapid-eye-movement episodes in narcolepsy: REM sleep pressure or non-REM-REM sleep dysregulation?. J. Sleep Res. 1, 245-250.
416. Takahashi, S. (1976) The action of tricyclics (alone or in combination with methylphenidate) upon several symptoms of narcolepsy. In: Narcolepsy (Advances in Sleep Research Vol. 3), pp. 625-638. Eds C. Guilleminault, W. C. Dement and P. Passouant. Spectrum Publications: New York.
417. Takahashi, Y. (1971) Narcoleptic syndrome and paradoxical sleep. Saishin-Igatu 26, 98-105.
418. Takahashi, Y. and Honda, Y. (1964) Pharmacotherapy in narcolepsy, Part 2: effects of thymoleptics and some other psychotropic drugs. Clin. Psychiat. (Jpn) 6, 775-784.
419. Takahashi, Y. and Jimbo, M. (1963) Polygraphic study of narcoleptic syndrome, with special reference to hypnagogic hallucinations and cataplexy. Folia Psychiat. Neurol. Jpn Suppl. 7, 343-347.
420. Takeuchi, T., Miyasita, A., Sasaki, Y., Inugami, M. and Fukuda, K. (1992) Isolated sleep paralysis elicited by sleep interruption. Sleep 15, 217-225.
421. Thompson, C., Schachter, M. and Parkes, J. D. (1982) Drugs for cataplexy. Ann. Neurol. 12, 62-63.
422. Thorpy, M., Snyder, M., Ledereich, P. and Starz, K. (1992) Short term triazolam improves nocturnal sleep of narcoleptics. Sleep 15, 212-216.
423. Thorpy, M. J. and Goswami, M. (1990) Treatment of narcolepsy. In: Handbook of Sleep Disorders, pp. 235-258. Eds M. J. Thorpy. Marcel Dekker, Inc.: New York.
424. Trulson, M. E. (1985) Simultaneous recording of substantia nigra neurons and voltammetric release of dopamine in the caudate of behaving cats. Brain Res. Bull. 15, 221-223.
425. Trulson, M. E. and Jacobs, B. L. (1979) Raphe unit activity in freely moving cats: correlation with level of behavioral arousal. Brain Res. 163, 135-150.
426. Valazquez-Mozezuma, J., Gillin, J. C. and Siromani, P. J. (1989) Effect of specific M1 and M2 muscarinic receptor agonists on REM sleep generation. Brain Res. 503, 128-131.
427. Valley, V. and Broughton, R. (1981) Daytime performance deficits and physiological vigilance in untreated patients with narcolepsy-cataplexy compared to controls. Rev. E.E.G. Neurophysiol. 11, 133-139.
428. Valley, V. and Broughton, R. (1983) The physiological (EEG) nature of drowsiness and its relation to performance deficits in narcoleptics. Electroencephalogr. Clin. Neurophysiol. 55, 243-251.
429. Van den Hoed, J., Kraemer, H., Guilleminault, C., V. P., Miles, L. E., Dement, W. C. and Mitler, M. M. (1981) Disorders of excessive daytime somnolence: polygraphic and clinical data for 100 patients. Sleep 4, 23-37.
430. Vanni-Mercier, G., Sakai, K., Lin, J. S. and Jouvet, M. (1989) Mapping of cholinoceptive brainstem structures responsible for the generation of paradoxical sleep in the cat. Arch. Ital. Biol. 127, 133-164.
431. Vaugh, B. V. and D'Cruz, O. F. (1996) Carbamazepine as a treatment for cataplexy. Sleep 19, 101-103.
432. Vogel, G. (1960) Studies in psychophysiology of dreams III. The dream of narcolepsy. Arch. Gen. Psychiat. 3, 421-428.
433. Vogel, G., Neill, D., Hagler, M. and Kors, D. (1990) A new animal model of endogenous depression: a summary of present findings. Neurosci. Biobehav. Rev. 14, 85-91.
434. Weiner, N. (1985) Norepinephrine, epinephrine, and the sympathomimetic amines. In: The Pharmacological Basis of Therapeutics, seventh edition, pp. 145-180. Eds A. G. Gilman, L. S. Goodman, W. R. Theodore and F. Murad. Macmillan: New York.
435. Westphal, C. (1877) Eigenthümliche mit Einschlafen verbundene Anfälle. Arch. Psychiat. 7, 631-635.
436. Wilson, S. A. K. (1927) The narcolepsies. Annu. Congr. Assoc. Phys. 3, 63-109.
437. Winter, E., Prendergast, M. and Green, A. (1996) Narcolepsy in a two-year-old boy. Dev. Med. Child Neurol. 38, 356-370.
438. Wisner, K., Perel, J. and Wheeler, S. (1993) Tricyclic requirements across pregnancy. Am. J. Psychiat. 150, 1541-1542.
439. Woolf, N. J., Hernit, M. C. and Butcher, L. L. (1986) Cholinergic and non-cholinergic projections from the rat basal forebrain revealed by combined choline acetyltransferase and phaseolus vulgaris leucoagglutinin immunohistochemistry. Neurosci. Lett. 66, 281-286.
440. Wooten, V. (1994) Effectiveness of yohimbine in treating narcolepsy. South. Med. J. 87, 1065-1066.
441. Wu, M., Gukyani, S., Mignot, E. and Siegel, J. (1996) Activity of REM off cells during cataplexy in the narcoleptic dog. Sleep Res. 25, 40.
442. Wurtman, R. J. and Zhdanova, I. (1995) Improvement of sleep quality by melatonin. Lancet 346, 1491.
443. Wyatt, R. J., Fram, D. H., Buchbinder, R. and Snyder, F. (1971) Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. NE J. Med. 285, 987-991.
444. Wyatt, R. J., Kupfer, D. J., Scott, J., Robinson, D. S. and Snyder, F. (1969) Longitudinal studies of the effect of monoamine oxidase inhibitors on the sleep in man. Psycopharmacologia (Berl.) 15, 236-244.
445. Wyler, A. R., Wilkus, R. J. and Troupin, A. S. (1975) Methysergide in the treatment of narcolepsy. Arch. Neurol. 32, 265-268.
446. Yamamoto, K. and Domino, E. F. (1967) Cholinergic agonist interactions on neocortical and limbic EEG activations. Intl J. Neuropharmacol. 6, 357-373.
447. Yoss, R. E. and Daly, D. D. (1957) Criteria for the diagnosis of the narcoleptic syndrome. Proc. Staff Mtg Mayo. 32, 320-328.
448. Yoss, R. E. and Daly, D. D. (1959) Treatment of narcolepsy with ritalin. Neurology 9, 171-173.
449. Yoss, R. E. and Daly, D. D. (1960a) Narcolepsy in children. Pediatrics 25, 1025-1033.
450. Yoss, R. E. and Daly, D. D. (1960b) Narcolepsy. Med. Clins North Am. 44, 953-967.
451. Young, D. and Scottville, W. B. (1938) Paranoid psychosis in narcolepsy and the possible danger of benzedrine treatment. Med. Clins North Am. May, 637-646.
452. Zarcone, V., Dement, W., Smythe, H., Hoddes, E. and Phillips, R. (1972) Oral 1-5-hydroxytryptophan in narcolepsy. In: The Association for the Psychophysiological Study of Sleep 11th Annual Meeting, pp. 151. New York.
453. Zwicker, J., Bruck, D., Parkes, J. D. and Broughton, R. J. (1995) Acute mood improvement after dextroamphetamine and methylphenidate in narcolepsy. J. Sleep Res. 4, 252-255.